Skip to content

Pain Medicine for Wound Care Procedures

The Effectiveness of Small Doses of Ketamine With Morphine on Decreasing Pain Responses During Open Wound Care

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00701909
Enrollment
12
Registered
2008-06-19
Start date
2008-06-30
Completion date
2009-04-30
Last updated
2024-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hallucinations, Hyperalgesia, Nausea, Pain Intensity, Vomiting, Wound Care

Keywords

wound care, procedural pain intensity, procedural hyperalgesia, wound care pain intensity, wound care hyperalgesia, Wound care pain quality, Level of drowsiness, level of nausea, Level of vomiting, Level of hallucinations, Level of dysphoria

Brief summary

This is a randomized double-blind study to determine if the administration of a small-dose of ketamine (an anesthetic)added to morphine (an opioid) contributes to reducing pain intensity during open wound care procedure (WCP)in patients who have had a traumatic injury and are in an Intensive Care Unit. Patients will be randomized to receive morphine plus saline (a placebo) or morphine plus ketamine before the WCP. The second time the patient is scheduled for WCP (no less than 24 hours), patients will be crossed over to receive the treatment they did not receive the first time. It is hypothesized that patients who receive the combination of morphine and ketamine will have better pain control during the procedure than patients who just receive morphine.

Detailed description

An open wound care procedure causes pain and sometimes the use of medication such as morphine alone does not adequately help to alleviate pain during this procedure. This study is being done to learn if the administration of another medication named ketamine by the vein in addition to morphine is more effective in alleviating pain during the wound cleansing procedure than the administration of morphine alone. Patients will be eligible for the study if they are 21 years and older, have an open surgical or traumatic wound with a duration of no more than 10 days, had a wound pain intensity score more than 3 in a scale of 0 to 10 where 0 is no pain and 10 is the worst pain imaginable during a previous wound care procedure, and have an intravenous access. A total of 50 patients with these same characteristics are expected to take part in this study. Patients who agree to take part in this study will, one day, receive receive an injection via the vein of morphine 0.05 mg per kilogram of their weight (maximum dose of 4 mg) and another of ketamine 0.25 mg per kilogram of their weight prior receiving the wound care procedure and, on the other day, will receive an injection via the vein of morphine 0.1 mg per kilogram of their weight (maximum dose of 8 mg) and another of saline prior receiving the wound care procedure. They will not be able to know if they receive ketamine or saline the first time or second time. Ketamine is a drug approved by the U.S. Food and Drug Administration (FDA) for anesthesia but not approved to provide analgesia (relieve pain). However, small doses of ketamine are used (out of its indications) in the clinical area to provide analgesia, and its analgesic properties have been studied by many researchers. Before the wound care procedure subjects will be asked to rate their wound pain intensity at rest at that moment and in the past 24 hours (including worst and average pain), overall pain intensity at rest at this moment and worst and average in the past 24 hours using a 0 to 10 scale where 0 is no pain and 10 is the worst pain imaginable. They will be given a list of common words that might describe their pain, and a body outline to indicate where the pain is. In addition, they will be asked to rate their level of sleepiness using a 0 to 10 scale where 0 is not at all sleepy and 10 is extremely sleepy. After removing the outer dressing, patients will be tested for pain sensitivity around the wound with a thin, short length of plastic (like a little straw), which will be pressed against their skin from the outside of the wound towards the wound and they will be asked to report a distinct change in perception. The first point where a painful, sore, or sharper feeling occurs will be marked in the skin to measure the distance of this mark to the wound. If no change in perception occurs, stimulation will be stopped 0.5 cm from the wound. This measure is experimental. Immediately after the wound care procedure the following will be measured: (1) worst wound pain intensity experienced during the wound care procedure, (2) description of pain quality during the wound care procedure, (3) level of sleepiness, (4) side effects such as unpleasant sensation will be measured using a 0 to 10 scale, where 0 means no unpleasant sensation at all and 10 means extremely unpleasant sensation, and finally (5) pain sensitivity around the wound using a thin, short length of plastic. The length of time needed to take part in this study will depend on how long the wound care procedure takes. The time could be approximately 45 minutes to 60 minutes (1 hour) per visit and 90 minutes (1½ hour) to 120 minutes (2 hours) in total for the study because 2 days are needed to complete the study.

Interventions

DRUGMorphine plus Ketamine

Morphine 0.05 mg/kg (maximum dose of 4 mg) IV plus Ketamine 0.25 mg/kg IV. Then, Morphine 0.1 mg/kg (maximum dose of 8 mg) IV plus Saline IV

DRUGMorphine plus Saline (placebo)

Morphine 0.1 mg/kg (maximum dose of 8 mg) IV plus Saline IV. Then, Morphine 0.05 mg/kg (maximum dose of 4 mg) IV plus Ketamine 0.25 mg/kg IV.

Sponsors

University of California, San Francisco
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
21 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Adults patients (≥ 21 years) have to have an open wound with duration of no more than 10 days that requires wound care * be able to self-report their pain * had a pain intensity score \> 3 during previous wound care procedure * has intravenous access

Exclusion criteria

* Patients with an injury that impairs sensation in the wound area according to a medical diagnosis * has an allergy to morphine or ketamine * has not received morphine previously * In addition, patients who are 65 years of age or older.

Design outcomes

Primary

MeasureTime frameDescription
Pain IntensityImmediately after the wound care procedureThe degree of pain described by participants on a numeric rating scale of 0 to 10, where 0 = no pain and 10 = worst pain imaginable

Secondary

MeasureTime frameDescription
Wound Pain QualityImmediately after the procedureShort-form McGill Pain Questionnaire. The questionnaire has 15 adjectives to describe the pain. Each is rated on a 4-point scale (i.e., none, mild, moderate, or severe. Total wound pain quality score can range from 0 to 45.

Countries

Puerto Rico, United States

Participant flow

Participants by arm

ArmCount
Morphine Plus Ketamine First
During the first wound care procedure, patients received morphine 0.05 mg/kg (maximum dose of 4 mg) plus ketamine 0.25 mg/kg. Then, during the second wound care procedure, they received morphine 0.1 mg/kg (maximum dose of 8 mg) plus saline.
7
Morphine Plus Saline First
During the first wound care procedure, patients received morphine 0.1 mg/kg (maximum dose of 8 mg) plus saline. Then, during the second wound care procedure, they received morphine 0.05 mg/kg (maximum dose of 4 mg) plus ketamine 0.25 mg/kg.
4
Total11

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyWithdrawal by Subject01

Baseline characteristics

CharacteristicMorphine Plus Ketamine FirstMorphine Plus Saline FirstTotal
Age, Continuous32.1 years
STANDARD_DEVIATION 9.6
32.5 years
STANDARD_DEVIATION 4.4
32.3 years
STANDARD_DEVIATION 7.8
Region of Enrollment
Puerto Rico
7 participants4 participants11 participants
Sex: Female, Male
Female
0 Participants0 Participants0 Participants
Sex: Female, Male
Male
7 Participants4 Participants11 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
10 / 110 / 11
serious
Total, serious adverse events
0 / 110 / 11

Outcome results

Primary

Pain Intensity

The degree of pain described by participants on a numeric rating scale of 0 to 10, where 0 = no pain and 10 = worst pain imaginable

Time frame: Immediately after the wound care procedure

ArmMeasureValue (MEAN)Dispersion
Morphine Plus KetaminePain Intensity3.1 score on a scaleStandard Error 0.99
Morphine Plus SalinePain Intensity6.8 score on a scaleStandard Error 0.92
Secondary

Wound Pain Quality

Short-form McGill Pain Questionnaire. The questionnaire has 15 adjectives to describe the pain. Each is rated on a 4-point scale (i.e., none, mild, moderate, or severe. Total wound pain quality score can range from 0 to 45.

Time frame: Immediately after the procedure

ArmMeasureValue (MEAN)Dispersion
Morphine Plus KetamineWound Pain Quality13.6 units on a scaleStandard Error 3.6
Morphine Plus SalineWound Pain Quality17.6 units on a scaleStandard Error 3.7

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026